GLPwatch
Liraglutide for HIV-associated Neurocognitive Disorder
NCT02743598 · Terminated
Last updated 2026-05-28This clinical trial is testing whether the medication liraglutide can improve brain function in adults living with HIV who also have type 2 diabetes, obesity, or metabolic syndrome.
Status Terminated Stopped early and will not restart.
Phase Phase 4 Monitors a drug already on the market.
Type Interventional (clinical trial)
Design open-label (no blinding) treatment study
Participants 4 people
Who can join Ages 18–65 · all sexes
Timeline Started 2016-09 · est. completion 2018-09
Where 1 site · United States
What this study is testing ClinicalTrials.gov NCT02743598 ↗
Description as written by the study sponsor.
This study will test the effect of liraglutide on cognitive function in HIV-infected overweight or obese subjects with type 2 diabetes.
Treatments tested
- Liraglutide Drug
| Main thing measured | Neurocognitive performance- change in global cognitive scores on a standard neuropsychological profile |
|---|---|
| Sponsor | Temple University |
| Conditions studied | HIV Infection, Diabetes Mellitus Type 2, Obesity, Overweight, Metabolic Syndrome |
| GLP-1 drugs | liraglutide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02743598 ↗